Carmen Sanges, PhD, University Hospital Würzburg, Würzburg, Germany, introduces T2Evolve, a European consortium to accelerate the development and improve access to CAR T-cell therapy while identifying the needs and gaps in the CAR-T journey to facilitate a faster solution process. The consortium engages with various stakeholders to develop a comprehensive understanding of the challenges experienced by patients throughout the CAR-T journey. The T2Evolve patient survey has allowed for feedback to be collected from hundreds of European patients receiving CAR-T, and the gaps that have been highlighted can be used to inform health system decision-makers. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.